185 related articles for article (PubMed ID: 34178677)
21. Immunotherapy in malignant pleural mesothelioma: a review of literature data.
Menis J; Pasello G; Remon J
Transl Lung Cancer Res; 2021 Jun; 10(6):2988-3000. PubMed ID: 34295692
[TBL] [Abstract][Full Text] [Related]
22. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.
Tazzari M; Brich S; Tuccitto A; Bozzi F; Beretta V; Spagnuolo RD; Negri T; Stacchiotti S; Deraco M; Baratti D; Camisaschi C; Villa A; Vergani B; Rivoltini L; Pilotti S; Castelli C
J Immunol Res; 2018; 2018():5804230. PubMed ID: 30510965
[TBL] [Abstract][Full Text] [Related]
23. Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma.
Xu X; Cheng L; Fan Y; Mao W
Front Oncol; 2020; 10():544789. PubMed ID: 33042835
[TBL] [Abstract][Full Text] [Related]
24. Novel immunotherapy clinical trials in malignant pleural mesothelioma.
Tano ZE; Chintala NK; Li X; Adusumilli PS
Ann Transl Med; 2017 Jun; 5(11):245. PubMed ID: 28706913
[TBL] [Abstract][Full Text] [Related]
25. Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
Riganti C; Lingua MF; Salaroglio IC; Falcomatà C; Righi L; Morena D; Picca F; Oddo D; Kopecka J; Pradotto M; Libener R; Orecchia S; Bironzo P; Comunanza V; Bussolino F; Novello S; Scagliotti GV; Di Nicolantonio F; Taulli R
Oncoimmunology; 2018; 7(3):e1398874. PubMed ID: 29399399
[TBL] [Abstract][Full Text] [Related]
26. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
Cedrés S; Ponce-Aix S; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Gómez-Abecia S; Zucchiatti AC; Sansano I; Enguita AB; Miquel JM; Viaplana C; Dienstmann R; Paz-Ares L; Felip E
Clin Transl Oncol; 2020 Aug; 22(8):1390-1398. PubMed ID: 31916017
[TBL] [Abstract][Full Text] [Related]
27. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
28. Therapies currently in Phase II trials for malignant pleural mesothelioma.
Pinton G; Manente AG; Tavian D; Moro L; Mutti L
Expert Opin Investig Drugs; 2013 Oct; 22(10):1255-63. PubMed ID: 23815672
[TBL] [Abstract][Full Text] [Related]
29. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S; Curioni-Fontecedro A; Dafni U; Shah R; O'Brien M; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Nadal E; Janthur WD; López Castro R; García Campelo R; Rusakiewicz S; Letovanec I; Polydoropoulou V; Roschitzki-Voser H; Ruepp B; Gasca-Ruchti A; Peters S; Stahel RA
Ann Oncol; 2020 Dec; 31(12):1734-1745. PubMed ID: 32976938
[TBL] [Abstract][Full Text] [Related]
30. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
31. Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma.
Cavin S; Gkasti A; Faget J; Hao Y; Letovanec I; Reichenbach M; Gonzalez M; Krueger T; Dyson PJ; Meylan E; Perentes JY
Eur J Cardiothorac Surg; 2020 Oct; 58(4):783-791. PubMed ID: 32372095
[TBL] [Abstract][Full Text] [Related]
32. Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.
Abbott DM; Bortolotto C; Benvenuti S; Lancia A; Filippi AR; Stella GM
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32392897
[TBL] [Abstract][Full Text] [Related]
33. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
34. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
Salaroglio IC; Kopecka J; Napoli F; Pradotto M; Maletta F; Costardi L; Gagliasso M; Milosevic V; Ananthanarayanan P; Bironzo P; Tabbò F; Cartia CF; Passone E; Comunanza V; Ardissone F; Ruffini E; Bussolino F; Righi L; Novello S; Di Maio M; Papotti M; Scagliotti GV; Riganti C
J Thorac Oncol; 2019 Aug; 14(8):1458-1471. PubMed ID: 31078776
[TBL] [Abstract][Full Text] [Related]
35. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
36. Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis.
Mohr S; Neuville A; Bottin MC; Micillino JC; Keith G; Rihn BH
Cancer Genomics Proteomics; 2005; 2(3):125-135. PubMed ID: 31394644
[TBL] [Abstract][Full Text] [Related]
37. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
Remon J; Reguart N; Corral J; Lianes P
Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
[TBL] [Abstract][Full Text] [Related]
38. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
39. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy and radiation therapy for malignant pleural mesothelioma.
Alley EW; Katz SI; Cengel KA; Simone CB
Transl Lung Cancer Res; 2017 Apr; 6(2):212-219. PubMed ID: 28529903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
